GNT-PHARMA
GNT Pharma has successfully completed a Phase III clinical trial for crisdesalazine , a new drug for treating canine cognitive dysfunction syndrome or Alzheimer’s disease.
In the clinical study conducted with 48 companion dogs with severe cognitive dysfunction at 7 veterinary hospitals including Seoul National University Animal Hospital, crisdesalazine-treated group demonstrated outstanding and significant efficacy compared to the placebo group in canine cognitive dysfunction rating scale, the primary outcome measure, as well as in canine dementia scale, the secondary outcome measure. Efficacy was identified both at the 4-week and 8-week treatment in companion dogs that received 5 mg/kg or 10 mg/kg of crisdesalazine. No adverse events were found in relation with the administration of crisdesalazine.
Davis research group at the University of California reported that 28% of companion dogs aged 11~12 and 68% of such dogs aged 15~16 suffer from cognitive dysfunction. As lifespan of companion dogs increases thanks to the advancement in veterinary science and healthcare, their dementia prevalence rate is on the rise. But the increase in companion dogs with dementia is emerging as a serious socio-economic problem due to the unavailability of treatment for dogs with dementia.
Crisdesalazine is a multi-target drug developed to provide strong antioxidant effect and safe anti-inflammatory action to prevent amyloid plaque, neurofibrillary tangle, and neurodegeneration that cause Alzheimer’s disease and companion dog’s dementia. Earlier, scientists at GNT Pharma proved that crisdesalazine reduced amyloid plaques and neuronal death while improving cognitive function in the Alzheimer’s disease mice models.
“Demonstration of safety and outstanding efficacy of crisdesalazine in companion dogs with dementia is a groundbreaking outcome and we recently filed an application for the PCT patent,” said Dr. Jin Hwan Lee, Head of GNT Pharma Animal Healthcare Division.
“We expect to complete its Phase II clinical study in 2~3 years for patients with Alzheimer’s disease,” said Dr. Byoung Joo Gwag, CEO of GNT Pharma and inventor of crisdesalazine. “We plan to submit an application to the Ministry of Food and Drug Safety in the second half year for the clinical study of crisdesalazine for treating Alzheimer’s disease.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005324/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
China Industry Leaders Convene in Jianshui to Chart the Blueberry Sector’s Growth Path22.12.2025 14:32:00 CET | Press release
The Third Yunnan Blueberry Conference and the release ceremony of the “Xinhua–Yunnan Honghe Blueberry Industry Development Index Report” opened on December 19 in Jianshui County, Honghe Hani and Yi Autonomous Prefecture, in southwest China’s Yunnan Province. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222516223/en/ The opening ceremony of the conference on 19th Dec in Jianshui. The conference has attracted scholars, experts, business representatives, and purchasers from across China, who have gathered here to explore pathways for promoting the high-quality development of the blueberry industry. During the three-day conference, organizers convened two major signing ceremonies: a cooperation agreement to jointly establish the Yunnan Blueberry Research Institute, and a strategic agreement to enhance financial support for the full industrial chain of Honghe blueberries. Outstanding organizations and individuals contributin
Modon Holding Forms Joint Venture With Related Companies and Panepinto Properties to Deliver Harborside 4, a Luxury Residential Tower Along the Waterfront in the Heart of Downtown Jersey City22.12.2025 14:17:00 CET | Press release
Modon acquires a majority equity stake in Harborside 4, a prime 54-story development scheme in downtown Jersey City which will deliver 800 luxury rental apartments and condos in Q1 2029Joint venture with Related and Panepinto supports Modon’s ongoing strategy to diversify its global portfolio through high quality investments and strong international partnerships Modon Holding PSC (“Modon”) today announced a new joint venture to deliver Harborside 4, a 54-story residential tower on one of the last prime waterfront sites in downtown Jersey City, New Jersey, USA. Modon will hold a majority equity stake alongside leading US developer Related Companies and long-established Jersey City firm Panepinto Properties (the “Joint Venture”), marking a further milestone in the Group’s strategy to scale its diversified global portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222455854/en/ Harborside 4 render (Photo: AETOSWire) Ha
Coulson Aviation Announces Launch of Boeing 767 VLAT Program22.12.2025 14:03:00 CET | Press release
Advancing the Next Generation of High-Capacity Aerial Firefighting Coulson Aviation USA has announced the launch of its Boeing 767 Very Large Airtanker (VLAT) program, marking a significant advancement in the evolution of aerial firefighting capability. The program is intended to provide a sustainable replacement for legacy VLAT platforms nearing the end of their operational service life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222917730/en/ A cross-sectional view of Coulson Aviation’s Boeing 767 Very Large Airtanker (VLAT) illustrates the integration of the RADS retardant delivery system and the next generation of high-capacity, sustainable aerial firefighting design. The recent grounding of the MD11 and DC10 fleets has highlighted a structural challenge for firefighting agencies worldwide. As older widebody aircraft are retired, the industry faces a significant reduction in high-capacity, large-scale retardant de
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom